132 related articles for article (PubMed ID: 9479598)
1. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
[No Abstract] [Full Text] [Related]
2. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
[TBL] [Abstract][Full Text] [Related]
3. IL-6 is a survival prognostic factor in renal cell carcinoma.
Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
[TBL] [Abstract][Full Text] [Related]
5. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
6. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Lissoni P; Brivio F; Viviani S; Fumagalli L
J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer.
Lissoni P; Rovelli F; Vellani D; Malugani F; Bucovec R; Chapovalenko L; Fumagalli E; Gardani G
Int J Biol Markers; 2001; 16(2):146-7. PubMed ID: 11471899
[No Abstract] [Full Text] [Related]
8. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
9. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
11. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
12. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
Lissoni P; Mandalà M; Brivio F
Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
[TBL] [Abstract][Full Text] [Related]
14. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
[TBL] [Abstract][Full Text] [Related]
16. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
17. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
18. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
19. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy.
Kedar I; Mermershtain W; Ivgi H
Int J Cancer; 2004 Jun; 110(2):260-5. PubMed ID: 15069691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]